Study Design: BESIVANCE was administered as a topical ocular instillation to human
subjects as part of a single-center, open-label study (N=64). At predetermined intervals after
dosing, ocular tear samples were collected and analyzed for besifloxacin levels.6
MIC90 values for P. aeruginosa, S. aureus, S. pneumoniae,
MRSE, MRSA, MSCoNS, MRCoNS, and H. influenzae are from the ARMOR 2015 surveillance study.
5 MIC90 values for S. epidermidis are from the BESIVANCE clinical
*MRSA-CR = ciprofloxacin-resistant MRSA; MRSE-CR = ciprofloxacin-resistant MRSE.
Clinical significance of these in vitro data has not been established.